PharmaEssentia Corporation: PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi (ropeginterferon alfa-2b-njft) in Latin America
PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, today announced that it has entered into an exclusive license agreement with Pint-Pharma GmbH